Jagsonpal Pharmaceuticals Limited — Investor Meet, 27-01-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Jagsonpal Pharma's Q3 FY26 saw flat revenue at 73 Cr, with PAT growing 10% YoY to 12.5 Cr (margin 17.1%). For the nine months, revenue grew 6% YoY to 223 Cr, and PAT rose 12.5% YoY to 35.9 Cr. Free cash balance hit 176 Cr. Management acknowledged Q3 was below expectations due to market headwinds and internal strategic realignments, including recalibrating field operations and rationalizing some small SKUs. A one-time 2.1 Cr exceptional cost was booked for the new labor code. The company expects double-digit growth from Q4 FY26, aiming for 50% above industry growth. Strategic focus areas include orthopedics and women's health. M&A is a priority, but valuations are high; cash may be returned to shareholders if efficient deployment isn't found. The tone is confident about future acceleration despite temporary Q3 softness.